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Introduction
Umbilical cord blood (UCB) is an alternative option to
standard graft sources for hematopoietic stem cell transplan-
tation (HSCT), and it has been successfully used in both chil-
dren and adults. Several studies comparing results of unrelat-
ed cord blood transplantation (UCBT) and either bone mar-
row or peripheral blood stem cell transplantation showed
similar results in terms of overall survival and leukemia-free
survival, in spite of slower hematopoietic recovery and a
higher incidence of graft failure for UCB transplant recipi-
ents.1-3 Possible reasons for delayed/failed engraftment
include the low stem cell content of UCB units, a higher
degree of HLA disparity in the donor/recipient pair and poor
T-cell function after UCBT, leading to a high rate of infec-
tions in the early post-transplant period. 
Graft failure is a life-threatening complication of all kinds of
HSCT and occurs more frequently after UCBT than after trans-
plants using other standard graft sources.3 Some authors have
reported that the overall incidence of graft failure after UCBT
is between 10% and 20%.3,4 Graft failure increases transplant-
related mortality because of the prolonged period of aplasia
when the recipient is at a higher risk of infection and hemor-
rhage. Importantly, the treatment of graft failure is not stan-
dardized.5,6 Either autologous rescue or second HSCT from a
related or unrelated donor can be considered, depending on the
availability of the additional graft and the needs of the individ-
ual patient. While autologous rescue is immediately available,
procurement of an allogeneic graft takes time; therefore, the
decision to initiate the search for a new graft, and the timing of
doing so and proceeding with the second transplant are of crit-
ical importance. A delay by the treating physician to initiate the
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Umbilical cord blood transplant recipients are exposed to an increased risk of graft failure, a complication leading
to a higher rate of transplant-related mortality. The decision and timing to offer a second transplant after graft failure
is challenging. With the aim of addressing this issue, we analyzed engraftment kinetics and outcomes of 1268
patients (73% children) with acute leukemia (64% acute lymphoblastic leukemia, 36% acute myeloid leukemia) in
remission who underwent single-unit umbilical cord blood transplantation after a myeloablative conditioning regi-
men. The median follow-up was 31 months. The overall survival rate at 3 years was 47%; the 100-day cumulative
incidence of transplant-related mortality was 16%. Longer time to engraftment was associated with increased trans-
plant-related mortality and shorter overall survival. The cumulative incidence of neutrophil engraftment at day 60
was 86%, while the median time to achieve engraftment was 24 days. Probability density analysis showed that the
likelihood of engraftment after umbilical cord blood transplantation increased after day 10, peaked on day 21 and
slowly decreased to 21% by day 31. Beyond day 31, the probability of engraftment dropped rapidly, and the resid-
ual probability of engrafting after day 42 was 5%. Graft failure was reported in 166 patients, and 66 of them
received a second graft (allogeneic, n=45). Rescue actions, such as the search for another graft, should be considered
starting after day 21. A diagnosis of graft failure can be established in patients who have not achieved neutrophil
recovery by day 42. Moreover, subsequent transplants should not be postponed after day 42. 
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ABSTRACT
search for a donor in anticipation of a second transplant
may result in fatal complications. Conversely, proceeding to
second transplant too early will counteract the residual
chances of engraftment from the primary transplant.
Second HSCT performed as rescue of graft failure is associ-
ated with a poor prognosis.7,8 The timing of rescue trans-
plantation varies between transplant centers and the trans-
planting physicians’ experience and, possibly, bias. It is,
therefore, desirable to have an evidence-based strategy to
determine the optimal timing of the second transplant; such
a strategy should be based on the probability of engraft-
ment at various time points after UCBT. The probability of
engraftment after transplantation follows the distribution of
a sinusoid curve.  Further, delayed and/or lower engraft-
ment probabilities are associated with higher transplant-
related mortality. In order to develop an evidence-based
strategy to facilitate decision-making and timing of second
transplantation, we analyzed engraftment kinetics and clin-
ical outcomes of patients who underwent unrelated UCBT
after a myeloablative conditioning regimen.
Methods
The study included all patients (n=1268) with a diagnosis of
acute leukemia in complete remission, transplanted with a single,
unrelated UCB unit following a myeloablative conditioning regi-
men between 1994 and 2011 at EBMT centers and reported to
Eurocord. The Institutional Review Boards of the Eurocord-
Netcord scientific committee approved this study.
Definitions and endpoints
Adults were defined as patients 18 years of age or more. The
conditioning regimen was defined as myeloablative when it con-
tained total body irradiation at a dose greater than 6 Gy, a dose of
oral busulfan greater than 8 mg/kg, or a dose of intravenous busul-
fan greater than 6.4 mg/kg. Neutrophil engraftment was defined as
an absolute neutrophil count greater than 0.5x109/L for three con-
secutive days. HLA compatibility was determined at the antigen
level for HLA-A and -B loci and at the allelic level for the HLA-
DRB1 locus. Full donor chimerism was defined as >95% of donor
cells and mixed chimerism as between 5% and 95% of donor cells.
The methods of analyzing chimerism  varied among transplant
centers. Graft failure was defined as failure to achieve an absolute
neutrophil count greater than 0.5x109/L or as achievement of an
absolute neutrophil count greater than 0.5x109/L without evidence
of autologous reconstitution. Transplant-related mortality was
defined as death in remission, and was considered as a competing
event for engraftment. Overall survival was defined as the proba-
bility of being alive, regardless of disease status, at any time point;
surviving patients were censored at last follow-up, and death was
considered an event. Leukemia-free survival was defined as the
probability of being alive and disease-free at any time point; both
death and relapse were considered events, and patients who were
alive and leukemia-free were censored at last follow-up. 
Statistical analysis
The probabilities of overall survival and leukemia-free survival
were calculated using the Kaplan-Meier method and the log-rank
test for univariate comparisons.9
The probability of neutrophil engraftment was investigated
through both conditional probability and probability density. The
probability density function for neutrophil engraftment was esti-
mated differentiating the cumulative incidence engraftment curve,
therefore describing the probability of engrafting at each time
point after UCBT, and taking into consideration competing events,
such as early deaths. The conditional probability is the probability
of neutrophil engraftment at each time point after UCBT, on con-
dition of having still not engrafted at that specific time point, and
it is estimated as the ratio between engrafted patients within each
time interval and patients at risk entering that interval. In this
study, time intervals of 5 days were chosen. The overall incidences
of graft failure and transplant-related mortality were calculated
with the cumulative incidence estimator.  
The following variables were tested in univariate analyses: age
at UCBT, type of leukemia, disease status, year of UCBT,
cytomegalovirus serostatus, HLA compatibility, ABO compatibili-
ty, total nucleated cell count at cryopreservation, use of total body
irradiation, and use of antithymocyte globulin. The time to
engraftment was used as a time-dependent covariate for trans-
plant-related mortality. The total nucleated cell count was ana-
lyzed as a continuous variable given the proportional increase of
total nucleated cell count with the age of the recipient.10,11
Adjusted multivariate analyses were performed using a Cox pro-
portional hazards regression model. All factors associated with a P
value less than 0.10 by univariate analysis were included in the
model. A stepwise backward procedure was then used with a cut-
off significance level of 0.05 for deleting factors in the model. All
tests were two-sided. The type I error rate was fixed at 0.05 for
determination of factors associated with time to event outcomes.
Statistical analyses were performed with SPSS 19 (SPSS Inc./IBM,
Armonk, NY, USA) and R 2.13.2 (R Development Core Team,
Vienna, Austria) software packages.
Please refer to the the online version of this article for a
Supplementary Appendix with a more comprehensive methods sec-
tion.
Results
The characteristics of the patients and their transplants
are summarized in Table 1; in brief, 813 patients were trans-
planted for acute lymphoblastic leukemia and 455 for acute
myeloid leukemia. Twelve percent of patients were HLA-
matched to the UCB unit, 45% were mismatched at one
HLA antigen, 40% at two antigens and 3% at more than
two antigens. The median total nucleated cell count at cryo -
preservation was 5.2x107/Kg (range, 1.1-34.8). All patients
received a myeloablative conditioning regimen, 50% based
on total body irradiation and 50% based on busulfan, and
87% received antithymocyte globulin before UCBT.
Engraftment and risk factors
The cumulative incidences of engraftment were 64% and
86% at 30 and 60 days after UCBT, respectively. Overall
1102 patients engrafted at a median time of 24 days (range,
10-116). The median time to engraftment was 25 days
(range, 11-108) for children and 23 days (range, 11-116) for
adult recipients (P=0.6). For patients who engrafted,
chimerism analysis within 100 days after UCBT confirmed
full donor chimerism in 98% of patients and showed mixed
chimerism in the other 2%. In the multivariate analysis
(Table 2), factors independently associated with greater
neutrophil engraftment were higher total nucleated cell
count at cryopreservation (P<0.001), age at UCBT
(P=0.001), and year in which the UCBT was performed
(after 2006) (P=0.002). 
The conditional probability of engraftment increased,
starting at 8.1% by 10-15 days after transplantation,
reached its peak at 33.2% by 25-30 days and thereafter rap-
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idly declined after day 40 to 6.1%, 50-55 days after trans-
plantation. The probability density analysis (Figure 1)
shows that the likelihood of engraftment after UCBT
increased after day 10, reached its peak at day 21 and
decreased slowly until day 31. The likelihood of engraft-
ment beyond day 31 was only 21% with a rapid decline
resulting in a residual probability of engraftment after day
42 of only 5%. The conditional probability of engraftment
was not different for children or adults. 
Graft failure
The cumulative incidence of graft failure at day 60 was
12%, being 11% for children and 12% for adults (P=0.64).
One-hundred and sixty-six patients were reported to have
experienced graft failure: of these patients, 13 (0.8%) are
alive with autologous reconstitution at a median of 45
months after UCBT, while 87 died without receiving any
treatment for graft failure (26 died before day 24 after
UCBT, and 61 died untreated at a median of 51 days after
UCBT (transplant-related deaths, n=43; relapse, n=17). The
remaining 66 patients who experienced graft failure
received a second graft. Twenty-one (32%) of these
received an autologous back-up at a median of 45 days
(range, 28-88) after the first UCBT; among them, eight
engrafted and five were alive at the last follow-up. The
remaining 45 patients (68%) underwent second allogeneic
transplantation at a median of 52 days (range, 21-152).
Information on donor source was available for 42 of these
45 patients. Rescue strategies included the following: (i)
peripheral blood stem cells from haploidentical family
members (n=17); (ii) second unrelated UCB unit (n=17); (iii)
peripheral blood stem cells from adult unrelated donors
(n=6); (iv) peripheral blood stem cells from a matched sib-
ling (n=1); and (v) a second UCB unit + peripheral blood
stem cells from a haploidentical family member (n=1). Most
of those patients received a fludarabine-based reduced
intensity conditioning. Thirty-one patients (71%) engrafted
at a median time of 15 days and eight patients experienced
grade II-IV acute graft-versus-host disease. Fifteen patients
are alive at a median of 12 months after the second HSCT.
The probability of overall survival after the second HSCT
was 37±10% and 29±7% after autologous and allogeneic
HSCT, respectively. No secondary graft failure was record-
ed in our series.
Transplant-related mortality 
The cumulative incidence of transplant-related mortality
was 16%, 23%, 29% and 33% at 100 days, 6 months, 12
months and 36 months, respectively. The main cause of
transplant-related deaths was infection (46%), followed by
graft-versus-host disease (22%), organ failure (16%), rejec-
tion (5%), hemorrhage (5%), interstitial pneumonia (4%)
and other (2%). 
In the multivariate analysis (Table 2), transplant-related
mortality was higher among adults (P=0.004), patients with
pre-transplant cytomegalovirus-positive serology (P=0.02),
and for those transplanted in second or subsequent com-
plete remission (P=0.001).
Engraftment kinetics after single UCBT
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Table 1. Characteristics of the patients and transplants.
Characteristics                                                              n=1268
Follow-up, median (range)                                              31 months (3-186)
Age at transplantation, median (range)                          9 years (0.3-64)
Adults (≥ 18 years)                                                                 338 (27%)
Children (<18 years)                                                              930 (73%)
Transplant year, median (range)                                     2006 (1994-2011)
Diagnosis                                                                                               
Acute lymphocytic leukemia                                                  813 (64%)
Acute myeloid leukemia                                                         455 (36%)
Recipient cytomegalovirus status                                                   
Negative                                                                                     516 (44%)
Patients’ weight, median (range)                                        31Kg (4-112)
Status at transplant                                                                             
1st complete remission                                                           603 (48%)
2nd complete remission                                                          567 (45%)
3rd complete remission or beyond                                         98 (8%)
HLA disparities                                                                                    
Children, 0-1 mismatch                                                          495 (64%)
Adult, 0-1 mismatch                                                                  100 (35%
Total nucleated cell count x107/Kg, median (range)
Entire population                                                                  5.2 (1.1-34.8)
Adults                                                                                       3.3 (1.1-20.4)
Children                                                                                   6.4 (0.2-41.8)
Conditioning regimen                                                                        
BU-based                                                                                     669 (50%)
CY+BU                                                                                       158 (13%)
CY+TBI                                                                                       238 (19%)
BU+Fluda+Thio                                                                       231 (19%)
CY+BU ± other                                                                        195 (16%)
Cy+VP16+TBI                                                                            112 (9%)
Other TBI-based                                                                        96 (8%)
Cy+Fluda+TBI                                                                            76 (6%)
Cy+Thio+TBI                                                                              74 (6%)
Other BU-based                                                                         37 (3%)
Other (includes treosulfan)                                                   14 (1%)
Missing information n=37                                                              
GVHD prophylaxis                                                                               
CsA±Pred                                                                                  887 (74%)
CsA+MMF±Pred                                                                      269 (23%)
Other                                                                                            40 (3%)
Missing information n=72                                                              
Use of ATG  before day+0                                                       990 (87%)
Kg: kilogram; HLA: human leukocyte antigen; BU: busulfan; CY: cyclophosphamide; Fluda:
fludarabine; Thio: thiothepa; TBI: total body irradiation; CsA: cyclosporine; Pred: prednisone;
MMF: mycophenolate mofetil; ATG: antithymocyte globulin; GVHD: graft-versus-host disease.
Table 2. Multivariate analysis.
HR 95% CI P value
Neutrophil engraftment
Age at UCBT ≥ 18 years 0.75 0.63-0.89 0.001
Year of  transplantation  ≥ 2006 0.97 0.95-0.99 0.002
TNC at cryopreservation (x107/Kg) 0.97 0.95-0.98 <0.001
Transplant-related mortality
Age at UCBT ≥ 18 years 1.42 1.11-1.80 0.004
Disease status not  CR1 1.47 1.17- 1.82 0.001
CMV positive serostatus 1.28 1.03-1.60 0.02
Relapse
Disease status CR1 0.60 0.47-0.76 <0.001
Leukemia-free survival
Diagnosis of ALL 1.32 1.11- 1.58 <0.001
Disease status not CR1 1.55 1.31- 1.85 <0.001
Age at UCBT ≥ 18 years 1.40 1.16- 1.70 <0.001
CMV positive serostatus 1.21 1.02- 1.43 0.02
HR: hazard ratio; CI: confidence interval; UCBT: umbilical cord blood transplantation;
TNC: total nucleated cells collected; Kg: kilogram; CR1: first complete remission; TRM:
transplant related mortality; CMV: cytomegalovirus.
Impact of time to engraftment on transplant-related 
mortality
Patients who achieved engraftment were divided into four
categories according to the interval to engraftment as fol-
lows: within 21 days, between 22 and 30 days, between 31
and 42 days and beyond 42 days from UCBT. The cumula-
tive incidence of transplant-related mortality according to
time to engraftment is shown in Figure 2A. Engraftment
beyond day 42 was associated with significantly higher
transplant-related mortality; the incidence rate of transplant-
related mortality was 25% for patients engrafting within 21
days, 29% for patients engrafting between 22-30 days, 30%
for those engrafting between 31-42 days, and 37% for those
who engrafted beyond 42 days (P=0.07).
Relapse, leukemia-free survival and overall survival 
The median follow-up was 31 months (range, 3-186
months). The cumulative incidence of relapse at 3 years
was 30% (24% for patients with acute myeloid leukemia
and 37% for those with acute lymphocytic leukemia;
P=0.004). In multivariate analysis (Table 2) first complete
remission at time of UCBT was the only factor associated
with a lower incidence of relapse (P<0.001).
The probability of overall survival at 3 years was 47±2%,
while that of leukemia-free survival was 43±2%. In multi-
variate analysis (Table 2), a diagnosis of acute lymphocytic
leukemia (P=0.002), disease status being second complete
remission or beyond (P<0.001), age at UCBT (P<0.001), and
pre-transplant cytomegalovirus-positive serology (P=0.02)
were independently associated with decreased leukemia-
free survival.  
Impact of time to engraftment on overall survival  
For patients who achieved engraftment, engraftment
beyond day 42 resulted in a lower probability of overall sur-
vival (Figure 2B) (overall survival at 3 years was 51% for
patients engrafting within 21 days, 52% for patients
engrafting between 22-30 days, 49% for those engrafting
between 31-42 days, and 44% beyond 42 days; P=0.13).
Discussion
Cord blood transplantation is associated with delayed
engraftment and graft failure. However, the clinical work-
up including the decision to initiate a donor search and the
timing of doing so in anticipation of a second transplant
remain unresolved issues.12 Some transplant centers have
adopted day 21 as the time to initiate the search for a
donor for a second transplant,13 others reserve a second
cord blood unit when the first cord blood unit is selected
for transplantation, or collect an autologous back-up,14 and
some advocate the use of haploidentical donor transplanta-
tion. In this study, the median times to infuse an autolo-
gous or allogeneic second graft were 45 days (range, 28-88)
and 52 days (range, 21-152), respectively. This information
suggests the need for more robust data to define engraft-
ment kinetics and recommendations on the optimal timing
for a donor search. With this aim, we conducted a registry-
based study in a large cohort of over 1000 patients.  We
observed that the probability of engraftment peaked at 21
days after UCBT, decreased gradually until day 31 and
rather rapidly thereafter, with engraftment being very
unlikely after day 42. One could argue that engraftment
kinetics may be different for children and adults, however,
A. Ruggeri et al.
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Figure 1. Probability density to engraftment. The curve shows the
ratio between engrafted patients and subjects at risk for each 5-day
interval from UCBT.
Figure 2. (A) Impact of engraftment time on transplant-related mortality (TRM); (B) Impact of engraftment time on overall survival. Solid line means
engraftment within 21 days of transplantation; dashed line means engraftment between 22 and 30 days after transplantation; Dotted line means
engraftment between 31 and 42 days after transplantation; Dotted-dashed line means engraftment more than 42 days after transplantation.
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we calculated the probability density to engraftment sepa-
rately for children and adults and did not find differences,
the residual probability of engraftment after day 42 being
5% in both groups. Taken together, our data support a
strategy of initiating a full work-up during the fourth week
after UCBT, including a search for viral infections such as
human herpes virus 6,15 determination of the degree of
chimerism and a bone marrow examination for patients
who have not engrafted by that time. The results of these
investigations will enable physicians to counsel patients
and their families and, if warranted, take the next step
which is to initiate a second donor search in preparation
for the second transplantation.  For patients who fail to
engraft, but achieve autologous recovery, there can be
more leniency regarding the time to perform a second
transplant, once patients are not neutropenic, and, conse-
quently, at high risk of non-relapse-related death.
However, due to the high risk of disease relapse in this
type of population, delaying the transplant much further
must be considered very carefully.  
In this study we analyzed engraftment kinetics through
the assessment of conditional probability and probability
density. The two methods provided similar results in terms
of probability trend to neutrophil engraftment. Conditional
probability is, however, affected by the low number of
subjects at risk in the later stages of the engraftment curve;
therefore, probability density gives a more accurate estima-
tion of the engraftment kinetics at the time points that are
the most relevant for the present analysis.
There are a number of factors that may be considered
when selecting the UCB unit for the primary transplant.  In
our analysis, total nucleated cell dose at freezing was asso-
ciated with engraftment. This variable is a major determi-
nant for outcomes in UCBT, and Eurocord and others have
demonstrated that a minimum cryopreserved total nucleat-
ed cell dose greater than 2.5-3x107/Kg is required to opti-
mize results of UCBT.
One limitation of this retrospective, multicenter, registry-
based study is the lack of standardization of the methods
used to evaluate engraftment. However, the difference in
chimerism methods among centers would probably not
have an impact on the definition of engraftment. Among
other factors in the multivariate analysis, disease status at
UCBT and the year of UCBT were both independently
associated with engraftment. Advances in UCB unit selec-
tion, taking into account the current knowledge about the
importance of a high dose of total nucleated cells and better
HLA matching16,17 (including the HLA-C locus and high res-
olution typing), and the selection of the most appropriate
conditioning regimen, whether myeloablative18 or reduced
intensity,19,20 may account for the improvement in the results
over the years. If and when high resolution typing and
HLA-C locus matching become standard practice, the
impact of HLA on engraftment kinetics  should be analyzed
in further studies.
The presence of anti-HLA antibodies in the recipient is a
known contributing factor to non-engraftment after UCBT.
Different studies found an increased risk of graft failure in
the presence of donor-specific anti-HLA antibodies in both
single and double UCBT after myeloablative conditioning
regimens21 and reduced intensity conditioning.22 However,
due the retrospective character of our study, we were not
able to analyze the impact of anti-HLA antibodies in this
series of UCBT recipients.
As expected, the interval from transplant to engraftment
influenced transplant-related mortality, this being higher
with increasing time to engraftment. Transplant-related
mortality is a leading cause of treatment failure after trans-
plantation, especially when graft failure occurs. In this
study, of the 166 recipients who failed to engraft only 40%
received a subsequent transplant. While we do not know
the reasons for not offering a second transplant, we specu-
late that clinical conditions, including life-threatening infec-
tions, could have been a major limitation coupled with the
transplant centers having lost the optimal window to search
for another donor. It is important to note that, in our series,
second transplants were performed after a median time of
45 days (range, 28-88) (autologous) and 52 days (range, 21-
152) (allogeneic) after the first UCBT, indicating that a sig-
nificant number of patients received a rescue procedure
more than 42 days after their first UCBT.  
The survival rate after a second transplant as rescue for
primary graft failure ranges from 10% to 30% in different
reports.23-26 The CIBMTR23 reported an 11% survival rate in
a large series of patients transplanted using a second unre-
lated donor (bone marrow or peripheral blood stem cells).
The median time between the first and second HSCT was
48 days. Guardiola et al.24 reported a 3-year overall survival
rate of 30% in 82 patients with hematologic diseases. They
showed that a longer interval between graft failure and sec-
ond HSCT was associated with a lower engraftment rate
and a lower probability of survival. McCann25 reported that
a delay of more than 60 days between a first and second
HSCT negatively affected the outcomes of 41 patients with
aplastic anemia. Despite these results, the optimal timing to
perform a second HSCT for patients with graft failure has
not yet been defined. 
A number of strategies have been proposed to reduce the
risk of graft failure after UCBT, including the use of multiple
units,27 intrabone infusion of the UCB unit,28 co-infusion of
purified stem cells from a haploidentical family donor,29,30
administration of molecules facilitating stem cell homing,31
and the co-infusion of ex-vivo expanded progenitor cells32,33
or mesenchymal stromal cells. All the above strategies were
reported to give promising results, but so far no definitive
conclusion can be drawn on their long-term outcome or
reproducibility. Physicians involved in UCBT programs
must frequently make difficult clinical decisions for patients
experiencing delayed engraftment. Some patients with graft
failure will eventually recover their autologous cells, but for
those who do not, the only treatment option is an addition-
al transplant or autologous rescue.34
To our knowledge, this is the first study looking at the
probability density of engraftment with the purpose of
identifying when engraftment is more likely to occur, and
determining the ideal time period to perform a subsequent
transplant in patients experiencing delayed engraftment or
graft failure. The results of this study will help transplant
physicians make faster, evidence-based decisions regarding
the treatment of early graft failure and the timing of initiat-
ing a further donor search. How this result will apply in the
setting of reduced intensity conditioning regimen or double
UCBT needs to be addressed in a different study.
In the case of autologous rescue, when cells have been
previously cryopreserved, the physician may choose to pro-
ceed with the rescue as soon as the patient approaches the
time window in which the likelihood of engraftment is low.
For patients needing another donor, the search can be initi-
ated early in order to proceed quickly to the subsequent
transplant. The selection of the optimal donor source for a
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second HSCT is challenging. UCB and haploidentical
donors both offer the possibility of shortening the delay of
donor procurement. In our series, the broad distribution of
graft sources for the second transplant in a relatively small
number of patients prevents us from making any indica-
tions about the optimal graft source.
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